Health Ministry expands QR code based traceability for vaccines, disinfectants and cancer drugs
The Union Health Ministry has introduced significant amendments to the Drugs Rules, bringing vaccines, anti-cancer drugs, antimicrobials, and medicines listed under the Narcotic Drugs and Psychotropic Substances (NDPS) Act under the ambit of Schedule H2. This regulatory update aims to strengthen drug traceability and ensure tighter control over the distribution and use of these critical medicines.
Schedule H2 is a special category under the Drugs and Cosmetics Rules which mandates the use of QR-code based traceability on packaging, allowing for real-time tracking of drug movement from manufacturer to end-user. This initiative helps prevent counterfeit drugs as well as unauthorized sales, protecting patient safety and supporting public health efforts.
According to official notifications, the phased implementation of this expanded drug traceability framework will commence from July 2027. This timeline offers stakeholders, including pharmaceutical manufacturers, distributors, and healthcare providers, sufficient time to upgrade their packaging and logistics systems to comply with the new regulations.
Experts have welcomed the move, emphasizing that incorporating vaccines and anti-cancer drugs under Schedule H2 will boost transparency and accountability in drug supply chains. The inclusion of antimicrobials can also play a crucial role in combating antimicrobial resistance by ensuring that antibiotics are dispensed responsibly and tracked meticulously.
The Ministry has underscored that the new rule changes are a step forward in India’s ongoing efforts to strengthen its drug regulatory framework in line with global best practices. It is expected to reduce incidences of drug fraud, enhance pharmacovigilance, and ultimately improve patient outcomes.
Industry representatives have indicated their support but have also called for clear guidelines and technical assistance to facilitate smooth adaptation, citing the complexity and costs involved in transitioning to QR code-enabled packaging.
Overall, this amendment reflects a robust policy approach aimed at safeguarding public health through innovation in drug regulation, emphasizing traceability, authenticity, and patient safety. Stakeholders are encouraged to prepare for the upcoming changes and participate actively in consultations and capacity-building programs.
For more updates on regulatory developments and implementation schedules, remain connected with official communications from the Health Ministry and the Central Drugs Standard Control Organization (CDSCO).
